Age and severe comorbidities were among the differences found when real-world data on Medicare patients receiving CAR T-cell therapy was compared to clinical trial outcomes, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Age and severe comorbidities were among the differences found when real-world data on Medicare patients receiving CAR T-cell therapy was compared to clinical trial outcomes, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Transcript:
What do we know about real-world use of CAR T-cell therapies and how the outcomes differ from those seen in clinical trials?
We have not compared outcomes in our study. We've not compared the outcomes directly to the trials. A good reason for that, one of our focuses in this study was on healthcare utilization as an outcome, pre versus post. In clinical trials, an awful lot of the utilization is prescribed by the protocol. That's a reason to do real-world analyses with these, so we can see what the decisions the clinicians are making when they're less constrained by the requirements of the protocol. We did, however, see one difference not in the care, but in the type of patients, the characteristics, of the patients that we're seeing. Average age of patients in the pivotal trials was 56 to 58 years of age. In our study, average age was 70, median was 71. Half of the patients in our trials were over 71. Another characteristic was presence of severe comorbidities. Over 50% of our patients had chronic heart disease, kidney disease, chronic obstructive pulmonary disease, and other serious conditions common in the elderly, common in this population. But the kinds of conditions that, in many cases, not in all, we have claims data. We don't always know the severity of these conditions, but they were present. So at least for some of the patients that we saw, again, over 50% of our patients had one of these conditions. These are conditions that, at least for some of the patients, would have led to them being excluded from the clinical trial. And we saw pretty positive outcomes coming from this.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More